Vistagen Therapeutics, Inc. Logo

Vistagen Therapeutics, Inc.

Biopharma firm developing intranasal therapies for anxiety, depression & neurological disorders.

VTGN | US

Overview

Corporate Details

ISIN(s):
US92840H2022
LEI:
Country:
United States of America
Address:
343 ALLERTON AVENUE, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing a new class of intranasal therapies for psychiatric and neurological disorders. The company leverages pioneering neuroscience and a deep understanding of nose-to-brain neurocircuitry to advance its pipeline of product candidates, known as "pherines." Vistagen's primary focus is on establishing new standards of care for conditions with large unmet needs, including anxiety and depression disorders. Its mission is to develop innovative, neurocircuitry-focused treatments to provide better outcomes for patients worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vistagen Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vistagen Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vistagen Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.